{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:08:26Z","timestamp":1791223706573,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s13402-013-0146-4","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T06:15:23Z","timestamp":1380521723000},"page":"449-457","source":"Crossref","is-referenced-by-count":26,"title":["PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic"],"prefix":"10.1007","volume":"36","author":[{"given":"Anne-Laure","family":"Papa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almas","family":"Sidiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Uma Aisvarya","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasmit","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Luchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiladitya","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Harfouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"146_CR1","volume-title":"Cancer Facts & Figures 2013","author":"American Cancer Society","year":"2013","unstructured":"American Cancer Society, Cancer Facts & Figures 2013 (American Cancer Society, Atlanta, 2013)"},{"key":"146_CR2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jama.2013.776","volume":"309","author":"RH Johnson","year":"2013","unstructured":"R.H. Johnson, F.L. Chien, A. Bleyer, Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA: J. Am. Med. Assoc. 309, 800\u2013805 (2013)","journal-title":"JAMA: J. Am. Med. Assoc."},{"key":"146_CR3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10456-009-9154-4","volume":"12","author":"R Harfouche","year":"2009","unstructured":"R. Harfouche, S. Basu, S. Soni et al., Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 12, 325\u2013338 (2009)","journal-title":"Angiogenesis"},{"key":"146_CR4","doi-asserted-by":"crossref","first-page":"075103","DOI":"10.1088\/0957-4484\/23\/7\/075103","volume":"23","author":"A Paraskar","year":"2012","unstructured":"A. Paraskar, S. Soni, B. Roy et al., Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology 23, 075103 (2012)","journal-title":"Nanotechnology"},{"key":"146_CR5","first-page":"90","volume":"62","author":"M Wang","year":"2010","unstructured":"M. Wang, M. Thanou, Targeting nanoparticles to cancer. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 62, 90\u201399 (2010)","journal-title":"Pharmacol. Res. Off. J. Ital. Pharmacol. Soc."},{"key":"146_CR6","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMra0912273","volume":"363","author":"BY Kim","year":"2010","unstructured":"B.Y. Kim, J.T. Rutka, W.C. Chan, Nanomedicine. N. Engl. J. Med. 363, 2434\u20132443 (2010)","journal-title":"N. Engl. J. Med."},{"key":"146_CR7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.chemphyslip.2012.03.003","volume":"165","author":"YC Barenholz","year":"2012","unstructured":"Y.C. Barenholz, D. Peer, Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. Chem. Phys. Lipids 165, 363\u2013364 (2012)","journal-title":"Chem. Phys. Lipids"},{"key":"146_CR8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","volume":"71","author":"JA Silverman","year":"2013","unstructured":"J.A. Silverman, S.R. Deitcher, Marqibo((R)) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol. 71, 555\u2013564 (2013)","journal-title":"Cancer Chemother. Pharmacol."},{"key":"146_CR9","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"H.A. Burris 3rd, M.J. Moore, J. Andersen et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 15, 2403\u20132413 (1997)","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"146_CR10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdr351","volume":"23","author":"JL Laethem Van","year":"2012","unstructured":"J.L. Van Laethem, C. Verslype, J.L. Iovanna et al., New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. \/ ESMO 23, 570\u2013576 (2012)","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. \/ ESMO"},{"key":"146_CR11","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"G.V. Scagliotti, P. Parikh, J. von Pawel et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 26, 3543\u20133551 (2008)","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"146_CR12","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"J. Pfisterer, M. Plante, I. Vergote et al., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 24, 4699\u20134707 (2006)","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"146_CR13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00000421-200106000-00011","volume":"24","author":"AM Murad","year":"2001","unstructured":"A.M. Murad, R.C. Guimaraes, B.C. Aragao et al., Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am. J. Clin. Oncol. 24, 264\u2013268 (2001)","journal-title":"Am. J. Clin. Oncol."},{"key":"146_CR14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00280-010-1369-y","volume":"67","author":"P Vici","year":"2011","unstructured":"P. Vici, A. Fabi, G. Metro et al., Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer Chemother. Pharmacol. 67, 687\u2013693 (2011)","journal-title":"Cancer Chemother. Pharmacol."},{"key":"146_CR15","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","volume":"26","author":"KS Albain","year":"2008","unstructured":"K.S. Albain, S.M. Nag, G. Calderillo-Ruiz et al., Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 26, 3950\u20133957 (2008)","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"146_CR16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1471-2407-12-419","volume":"12","author":"AL Papa","year":"2012","unstructured":"A.L. Papa, S. Basu, P. Sengupta et al., Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer 12, 419 (2012)","journal-title":"BMC Cancer"},{"key":"146_CR17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","volume":"1151","author":"G Haran","year":"1993","unstructured":"G. Haran, R. Cohen, L.K. Bar et al., Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151, 201\u2013215 (1993)","journal-title":"Biochim. Biophys. Acta"},{"key":"146_CR18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ctrv.2009.02.005","volume":"35","author":"K Pliarchopoulou","year":"2009","unstructured":"K. Pliarchopoulou, D. Pectasides, Pancreatic cancer: current and future treatment strategies. Cancer Treat. Rev. 35, 431\u2013436 (2009)","journal-title":"Cancer Treat. Rev."},{"key":"146_CR19","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1073\/pnas.0611660104","volume":"104","author":"MR Kano","year":"2007","unstructured":"M.R. Kano, Y. Bae, C. Iwata et al., Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 104, 3460\u20133465 (2007)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"146_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","volume":"69","author":"M Gaumet","year":"2008","unstructured":"M. Gaumet, A. Vargas, R. Gurny et al., Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 69, 1\u20139 (2008)","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"key":"146_CR21","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1016\/j.biomaterials.2009.02.040","volume":"30","author":"T Lammers","year":"2009","unstructured":"T. Lammers, V. Subr, K. Ulbrich et al., Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30, 3466\u20133475 (2009)","journal-title":"Biomaterials"},{"key":"146_CR22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00280-009-0957-1","volume":"64","author":"D Cosco","year":"2009","unstructured":"D. Cosco, A. Bulotta, M. Ventura et al., In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother. Pharmacol. 64, 1009\u20131020 (2009)","journal-title":"Cancer Chemother. Pharmacol."},{"key":"146_CR23","doi-asserted-by":"crossref","first-page":"C195","DOI":"10.1152\/ajpcell.1994.267.1.C195","volume":"267","author":"RJ Gillies","year":"1994","unstructured":"R.J. Gillies, Z. Liu, Z. Bhujwalla, 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am. J. Physiol. 267, C195\u2013C203 (1994)","journal-title":"Am. J. Physiol."},{"key":"146_CR24","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","volume":"73","author":"V Estrella","year":"2013","unstructured":"V. Estrella, T. Chen, M. Lloyd et al., Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 73, 1524\u20131535 (2013)","journal-title":"Cancer Res."},{"key":"146_CR25","doi-asserted-by":"crossref","first-page":"e24374","DOI":"10.1371\/journal.pone.0024374","volume":"6","author":"RR Arvizo","year":"2011","unstructured":"R.R. Arvizo, O.R. Miranda, D.F. Moyano et al., Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PloS One 6, e24374 (2011)","journal-title":"PloS One"},{"key":"146_CR26","doi-asserted-by":"crossref","unstructured":"S. Lerch, M. Dass, A. Musyanovych, et al., Polymeric nanoparticles of different sizes overcome the cell membrane barrier. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, (2013)","DOI":"10.1016\/j.ejpb.2013.01.024"},{"key":"146_CR27","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/smll.201200398","volume":"8","author":"R Luo","year":"2012","unstructured":"R. Luo, B. Neu, S.S. Venkatraman, Surface functionalization of nanoparticles to control cell interactions and drug release. Small 8, 2585\u20132594 (2012)","journal-title":"Small"},{"key":"146_CR28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nano.2008.02.003","volume":"4","author":"C Celia","year":"2008","unstructured":"C. Celia, N. Malara, R. Terracciano et al., Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells. Nanomed. Nanotechnol. Biol. Med. 4, 155\u2013166 (2008)","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"146_CR29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2217\/17435889.2.5.735","volume":"2","author":"J Suh","year":"2007","unstructured":"J. Suh, K.L. Choy, S.K. Lai et al., PEGylation of nanoparticles improves their cytoplasmic transport. Int. J. Nanomedicine 2, 735\u2013741 (2007)","journal-title":"Int. J. Nanomedicine"},{"key":"146_CR30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0003-9861(02)00725-7","volume":"410","author":"MR Almofti","year":"2003","unstructured":"M.R. Almofti, H. Harashima, Y. Shinohara et al., Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization. Arch. Biochem. Biophys. 410, 246\u2013253 (2003)","journal-title":"Arch. Biochem. Biophys."},{"key":"146_CR31","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11095-012-0952-9","volume":"30","author":"M Kapoor","year":"2013","unstructured":"M. Kapoor, D.J. Burgess, Cellular uptake mechanisms of novel anionic siRNA lipoplexes. Pharm. Res. 30, 1161\u20131175 (2013)","journal-title":"Pharm. Res."},{"key":"146_CR32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/bj20031253","volume":"377","author":"J Rejman","year":"2004","unstructured":"J. Rejman, V. Oberle, I.S. Zuhorn et al., Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377, 159\u2013169 (2004)","journal-title":"Biochem. J."},{"key":"146_CR33","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3892\/ijo.2012.1648","volume":"41","author":"K Quint","year":"2012","unstructured":"K. Quint, M. Tonigold, P. Di Fazio et al., Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int. J. Oncol. 41, 2093\u20132102 (2012)","journal-title":"Int. J. Oncol."},{"key":"146_CR34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2011.01.024","volume":"152","author":"FM Kievit","year":"2011","unstructured":"F.M. Kievit, F.Y. Wang, C. Fang et al., Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J. Control. Release Off. J. Control. Release Soc. 152, 76\u201383 (2011)","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"146_CR35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/nnm.10.35","volume":"5","author":"X Dong","year":"2010","unstructured":"X. Dong, R.J. Mumper, Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 5, 597\u2013615 (2010)","journal-title":"Nanomedicine (Lond)"},{"key":"146_CR36","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/sj.bjc.6604409","volume":"98","author":"V Adamo","year":"2008","unstructured":"V. Adamo, V. Lorusso, R. Rossello et al., Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent\/metastatic breast cancer: a multicentre phase II study. Br. J. Cancer 98, 1916\u20131921 (2008)","journal-title":"Br. J. Cancer"},{"key":"146_CR37","first-page":"S7-2","volume":"24","author":"AM Storniolo","year":"1997","unstructured":"A.M. Storniolo, S.R. Allerheiligen, H.L. Pearce, Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin. Oncol. 24, S7-2\u2013S7-7 (1997)","journal-title":"Semin. Oncol."},{"key":"146_CR38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MPA.0b013e31819436e6","volume":"38","author":"R Graeser","year":"2009","unstructured":"R. Graeser, C. Bornmann, N. Esser et al., Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas 38, 330\u2013337 (2009)","journal-title":"Pancreas"},{"key":"146_CR39","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"W.J. Gradishar, S. Tjulandin, N. Davidson et al., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 23, 7794\u20137803 (2005)","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"146_CR40","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","volume":"27","author":"WJ Gradishar","year":"2009","unstructured":"W.J. Gradishar, D. Krasnojon, S. Cheporov et al., Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 3611\u20133619 (2009)","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-013-0146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13402-013-0146-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-013-0146-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T22:05:23Z","timestamp":1564178723000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13402-013-0146-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1007\/s13402-013-0146-4","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}